

Mass Adjustment for Blood Factors for Impacted Claims Submitted January 1, 2022, through October 25, 2022

June 17, 2024

Background

The purpose of this alert is to inform pharmacy providers that Medi-Cal Rx initiated a mass adjustment related to blood factor hemophilia products Alprolix®, Eloctate®, and NovoSeven® for claims submitted on or after January 1, 2022, through October 25, 2022.

What Pharmacy Providers Need to Know

Medi-Cal Rx identified a claims processing issue affecting a select number of claims submitted on or after January 1, 2022, through October 25, 2022, for the hemophilia drugs Alprolix, Eloctate, and NovoSeven with NDCs 00169720801, 71104080101, 71104080201, 71104080301, 71104080401, 71104080501, 71104080601, 71104080701, 71104080801, 7110409101, 71104092201, 71104093301, 71104094401, 71104096601, and 71104097701. Medi-Cal Rx updated the average sales price (ASP) for these NDCs on October 25, 2022, to correctly calculate reimbursement for blood factor claims per the Department of Health Care Services' (DHCS) policy.

Medi-Cal Rx has identified the impacted net paid claims and will be adjusting these claims on behalf of pharmacy providers which may result in an amount owed to you, an amount you owe DHCS, or no net change to the amount you were already reimbursed. Medi-Cal Rx will complete the claim adjustments in stages over the next several months.

Adjustments have been made for some of the impacted claims submitted January 1, 2022, through October 25, 2022, and appeared on the June 14, 2024, remittance advice (RA). Adjustments for the remaining claims submitted January 1, 2022, through October 25, 2022, will be processed by Medi-Cal Rx at a later date and a separate alert will be provided when that adjustment commences.

What Pharmacy Providers Need to Do

No action is required by pharmacy providers at this time.

Adjustments for the impacted claims submitted January 1, 2022, through October 25, 2022, are included on the June 14, 2024 RA. On the RA, impacted pharmacy providers will see a reversal of the original claim and a new claim processed (same member, Rx number, date of service, NDC, etc.) to reflect the adjustment.

Mass Adjustment for Blood Factors for Impacted Claims Submitted January 1, 2022, through October 25, 2022 For more information about this and other mass adjustment activities, refer to the <u>Mass Adjustments</u> page located on the <u>Medi-Cal Rx Provider Portal</u> or send a secured email to <u>MediCalRxEducationOutreach@primetherapeutics.com</u> and include, if appropriate, any claim-specific information with the correspondence.

Contact Information

If you have any questions regarding the mass adjustment, call the Medi-Cal Rx Customer Service Center (CSC) at 1-800-977-2273, which is available 24 hours a day, 7 days a week, 365 days per year.

For other questions, email Medi-Cal Rx Education & Outreach at MediCalRxEducationOutreach@primetherapeutics.com.